Edith Cowan University

Research Online
Research outputs 2014 to 2021
2021

Prevention of dementia using mobile phone applications
(PRODEMOS): Protocol for an international randomised controlled
trial
Esmé Eggink
Melanie Hafdi
Marieke P. Hoevenaar-Blom
Manshu Song
Edith Cowan University

Sandrine Andrieu

See next page for additional authors

Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013
Part of the Neurosciences Commons
10.1136/bmjopen-2021-049762
Eggink, E., Hafdi, M., Hoevenaar-Blom, M. P., Song, M., Andrieu, S., Barnes, L. E., … Richard, E. (2021). Prevention of
dementia using mobile phone applications (PRODEMOS): Protocol for an international randomised controlled trial.
BMJ Open, 11(6), article e049762. https://doi.org/10.1136/bmjopen-2021-049762
This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworkspost2013/10433

Authors
Esmé Eggink, Melanie Hafdi, Marieke P. Hoevenaar-Blom, Manshu Song, Sandrine Andrieu, Linda E.
Barnes, Cindy Birck, Rachael L. Brooks, Nicola Coley, Elizabeth Ford, Jean Georges, Abraham van der
Groep, Willem A. Van Gool, Ron Handels, Haifeng Hou, Dong Li, Hongmei Liu, Jihui Lyu, Harm van Marwijk,
Mark van der Meijden, Yixuan Niu, Shanu Sadhwani, Wenzhi Wang, Youxin Wang, Anders Wimo, Xiaoyan
Ye, Yueyi Yu, Qiang Zeng, Wei Wang, Carol Brayne, Eric P. Moll van Charante, and Edo Richard

This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworkspost2013/10433

Open access

Protocol

Esmé Eggink  ,1 Melanie Hafdi,2 Marieke P Hoevenaar-Blom,2 Manshu Song,3,4
Sandrine Andrieu,5,6 Linda E Barnes,7 Cindy Birck,8 Rachael L Brooks,7
Nicola Coley  ,5,6 Elizabeth Ford  ,9 Jean Georges,8 Abraham van der Groep,10
Willem A van Gool,11 Ron Handels,12,13 Haifeng Hou,4,14 Dong Li,14 Hongmei Liu,15
Jihui Lyu  ,16 Harm van Marwijk  ,9 Mark van der Meijden,10 Yixuan Niu,17
Shanu Sadhwani,9 Wenzhi Wang  ,15 Youxin Wang,3,4 Anders Wimo,13
Xiaoyan Ye,18 Yueyi Yu,19 Qiang Zeng,20 Wei Zhang,21 Wei Wang,3,4 Carol Brayne,7
Eric P Moll van Charante,1,11 Edo Richard11,22

To cite: Eggink E, Hafdi M,
Hoevenaar-Blom MP, et al.
Prevention of dementia using
mobile phone applications
(PRODEMOS): protocol for
an international randomised
controlled trial. BMJ Open
2021;11:e049762. doi:10.1136/
bmjopen-2021-049762
►► Prepublication history and
supplemental material for this
paper is available online. To
view these files, please visit
the journal online (http://dx.doi.
org/10.1136/bmjopen-2021-
049762).

Received 02 February 2021
Accepted 14 May 2021

© Author(s) (or their
employer(s)) 2021. Re-use
permitted under CC BY.
Published by BMJ.
For numbered affiliations see
end of article.
Correspondence to
Professor Edo Richard;
e.richard@a msterdamumc.nl

ABSTRACT
Introduction Profiles of high risk for future dementia
are well understood and are likely to concern mostly
those in low-income and middle-income countries and
people at greater disadvantage in high-income countries.
Approximately 30%–40% of dementia cases have been
estimated to be attributed to modifiable risk factors,
including hypertension, smoking and sedentary lifestyle.
Tailored interventions targeting these risk factors can
potentially prevent or delay the onset of dementia. Mobile
health (mHealth) improves accessibility of such prevention
strategies in hard-to-reach populations while at the same
time tailoring such approaches. In the current study, we
will investigate the effectiveness and implementation of a
coach-supported mHealth intervention, targeting dementia
risk factors, to reduce dementia risk.
Methods and analysis The prevention of dementia using
mobile phone applications (PRODEMOS) randomised
controlled trial will follow an effectiveness–implementation
hybrid design, taking place in the UK and China. People are
eligible if they are 55–75 years old, of low socioeconomic
status (UK) or from the general population (China);
have ≥2 dementia risk factors; and own a smartphone.
2400 participants will be randomised to either a coach-
supported, interactive mHealth platform, facilitating self-
management of dementia risk factors, or a static control
platform. The intervention and follow-up period will be
18 months. The primary effectiveness outcome is change
in the previously validated Cardiovascular Risk Factors,
Ageing and Incidence of Dementia dementia risk score.
The main secondary outcomes include improvement
of individual risk factors and cost-effectiveness.
Implementation outcomes include acceptability, adoption,
feasibility and sustainability of the intervention.
Ethics and dissemination The PRODEMOS trial is
sponsored in the UK by the University of Cambridge and
is granted ethical approval by the London—Brighton
and Sussex Research Ethics Committee (reference: 20/
LO/01440). In China, the trial is approved by the medical

Strengths and limitations of this study
►► The coach-
supported mobile health intervention

builds on the previously developed Healthy Ageing
Through Internet Counselling in the Elderly electronic health platform, which was shown to improve cardiovascular risk of elderly in the Netherlands, France
and Finland.
►► The main strengths of the present study are testing
the approach in populations with low socioeconomic
status or different cultural settings and measuring
whether sustained involvement of end users can
be achieved, facilitating cultural adaptation of the
application.
►► Limitations of this study include the impossibility
to completely blinding the participants, potentially
leading to contamination, and the challenge to sufficiently engage the hard-to-reach target population.

ethics committees of Capital Medical University, Beijing
Tiantan Hospital, Beijing Geriatric Hospital, Chinese
People’s Liberation Army General Hospital, Taishan Medical
University and Xuanwu Hospital. Results will be published
in a peer-reviewed journal.
Trial registration number ISRCTN15986016.

INTRODUCTION
With global ageing, the prevalence of
dementia is expected to increase to over 130
million in 2050, especially in low-
income
and middle-
income countries (LMIC) and
in people from low socioeconomic status
(SES) background in high-income countries
(HIC).1 2 Strategies need to be developed that
aim to reduce the risk of dementia—many of
which will be at community and population
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cardiovascular risk factors via lifestyle changes, building
on the existing HATICE internet platform. Our aim is to
assess the effectiveness and implementation of this smartphone intervention on dementia risk in older people at
increased risk of dementia from a low-SES population
in the UK and from the general population in Beijing,
China.

METHODS
Study design
Prevention of dementia using mobile phone applications (PRODEMOS) is a multinational, prospective,
randomised, open-
label blinded endpoint trial with
18-month intervention and follow-up. The study follows
a hybrid effectiveness–implementation design, taking a
dual focus on assessing effectiveness and implementation
outcomes.26 27 The Amsterdam University Medical Centre
(Amsterdam UMC) is the coordinating centre.
Study population and recruitment
The study population will consist of community-dwelling
older adults aged 55–75 years old, of low SES in the UK
and of any SES in China, who have ≥2 dementia risk
factors and own a smartphone. Low SES in the UK is
operationalised as living in a postal code area ranked as
equal to or less than the lowest third decile of the index of
multiple deprivation.28 Eligibility criteria are similar for
both countries, except for criteria for obesity, based on
differences in national prevention guidelines29 (box 1).
Recruitment will take place in the Eastern Clinical Research Network (National Institutes of Health
Research) region of the UK and in the Beijing and
Tai’an cities, China. In the UK, recruitment has started
in January 2021 and will be undertaken by approximately
10–15 general practioner (GP) practice. A random
computer selection of participants living in the designated postal code areas meeting the age criterion and
having ≥1 known dementia risk factor according to the
GP registry will be approached through an information
letter, inviting them to contact the local study centre. In
China, participants will be recruited from seven hospitals
through advertisements on hospital websites, targeted
recruitment via local social media (WeChat) or direct
approach by nurses and physicians. In China, recruitment is expected to start mid-2021.
Intervention and control condition
Central to our study is the PRODEMOS platform, which
interconnects the assessor portal, the participant app and
the coach portal (figure 1). The assessor portal facilitates blinded collection of baseline and outcome assessments for all participants. The intervention and control
condition are both delivered through a smartphone app,
which, in the case of intervention participants, allows
communication with the coach portal. Data from the
assessor portal, participant app and coach portal can
be extracted through a researcher portal and stored in
Eggink E, et al. BMJ Open 2021;11:e049762. doi:10.1136/bmjopen-2021-049762
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level, but those that are individually based must be effective, affordable and easily implementable across various
healthcare settings.
Up to 40% of dementia cases are estimated to be attributable to potentially modifiable risk factors,3 of which
10%–20% are cardiovascular risk factors including hypertension, midlife obesity, dyslipidaemia, diabetes, smoking
and physical inactivity.4–6 To date, intervention studies
aiming to reduce dementia risk by targeting one or more
of these risk factors have shown inconsistent results.7 8
Results from randomised controlled trials (RCT) on blood
pressure-
lowering treatment have suggested a beneficial effect on dementia risk, although not consistently
and convincingly.9–11 Since the presence of multiple risk
factors may pose an additive or even synergistic effect on
dementia risk,12 13 targeting several risk factors simultaneously may be more effective. The only study to date
designed to address this question using dementia as
primary outcome did not show a statistically significant
effect after 6–8 years of intervention, although subgroup
analysis suggested benefit for those with untreated hypertension at baseline.14
A considerable challenge when designing a dementia
prevention trial is the time lag between the optimal
timing of the intervention and the onset of dementia.
Using incident dementia as primary outcome requires
large sample sizes and/or long follow-up periods to reach
statistical power.15 16 Dementia risk scores could be used
as a proxy, especially in trials with follow-up periods up to
several years. Another challenge, possibly explaining the
neutral results of intervention studies so far, is the small
window for risk factor improvement given a background
of high-quality cardiovascular risk management in HIC
where these studies were performed.17 This lends further
support for targeting people in LMIC and low-SES populations in HIC.
Digital health interventions have the potential to
improve cardiovascular risk factors in middle age and
beyond, especially when offered with human coaching
(blended care).18 In the Healthy Ageing Through
Internet Counselling in the Elderly (HATICE) trial, we
recently demonstrated that a coach-supported internet
intervention facilitating self-
management of cardiovascular risk factors can reduce older adults’ cardiovascular
risk over a static control platform, both in high and low
socioeconomic participant subgroups.19 Currently, digital
health interventions are increasingly offered through
smartphones. Smartphone penetration rates are especially high in HIC,20 also among people with low SES. In
2018, 67% of people with the lowest SES in UK owned
a smartphone.21 Approximately 40%–50% of the LMIC
population is connected to mobile internet,20 22 with
rates up to 60% in China.23 This renders mobile health
(mHealth) a promising method for health delivery in
underserved populations, including the improvement of
cardiovascular risk factors.24 25
We have developed a coach-supported mHealth intervention to reduce dementia risk by addressing common

Open access
Overview of inclusion and exclusion criteria

Inclusion criteria
►► Age ≥55 years and ≤75 years old.
►► Living in a postal code area ranked as equal to or less than the

lowest third decile of IMD*.
►► Good proficiency of the national language (English in UK and

Mandarin in China).
►► Possession of a smartphone.
►► ≥ Two dementia risk factors:

–– Insufficient physical activity (self-reported intermediate or vigorous activity of <150 min per week).
–– Active smoking (self-reported use of any sort of tobacco in any
quantity).
–– Depression (by meeting at least one of the following criteria):
–– Current diagnosis by specialist or GP.
–– History of treatment for depression (ie, drug therapy or
psychotherapy).
–– Manifest cardiovascular disease, as diagnosed by specialist or
GP.
–– Diabetes mellitus (by meeting at least one of the following
criteria):
–– Diagnosed by specialist or GP.
–– Use of insulin or other blood glucose-lowering medication.
–– Hypertension (by meeting at least one of the following criteria):
–– Diagnosed by specialist or GP.
–– Use of blood pressure-lowering medication.
–– Mean of baseline blood pressure measurements of ≥140 (systolic) or ≥90 (diastolic).
–– Obesity (by meeting at least one of the following criteria):
–– BMI ≥30 (UK) and ≥28 (China).
–– Baseline waist circumference ≥102 cm (men in UK), 90 cm
(men in China), 88 cm (women in UK) and 85 cm (women in
China).
–– Dyslipidaemia (by meeting at least one of the following criteria):
–– Diagnosed by specialist or GP.
–– Use of lipid-lowering medication.
–– Baseline total cholesterol ≥5.0 mmol/L*.

Exclusion criteria
►► Manifest dementia, as diagnosed by specialist or GP.
►► MMSE <24 (participants with ISCED level of >1) and MMSE <21

(participants with ISCED level of 1).
►► Any condition expected to limit 18-month follow-up, including me-

tastasised malignancy or other terminal illnesses.
►► Smartphone illiteracy, defined as not being able to send a message

from a smartphone.
►► Visual impairment interfering with operation of a smartphone.
►► Participating in another RCT on behaviour change.
►► Present severe alcohol or illicit drug abuse.
*Applies only to participants in the UK.
BMI, Body Mass Index; GP, general practitioner; IMD, Index of Multiple
Deprivation; ISCED, International Standard Classification of Education; MMSE,
Mini-Mental State Examination; RCT, randomised controlled trial.

a central database. The PRODEMOS platform was built
in close collaboration between software developers
and researchers from Amsterdam UMC, University of
Cambridge, Brighton and Sussex Medical School, Capital
Medical University in Beijing, health coaches and representatives of the target population from both countries.
Eggink E, et al. BMJ Open 2021;11:e049762. doi:10.1136/bmjopen-2021-049762

The internet platform previously used in the HATICE
trial served as the basis for the PRODEMOS platform.30
In addition to the transition of the participants’ end into
a mobile app, adjustments were made to the platform in
repeated cycles of interaction with end users. In an iterative process, experiences, needs and wishes from the
target population and health coaches regarding the app
and coach support, gained through interviews and focus
groups, served as a guideline for further development.
Participants have only access to one of two versions
of the participant app. Participants randomised to the
intervention condition will have access to an interactive
smartphone application in their own language (English
in the UK and Mandarin in China). The intervention
app facilitates coach-supported self-management of seven
dementia risk factors, including overweight, unhealthy
diet, insufficient physical activity, smoking, hypertension, dyslipidaemia and diabetes. Participants can set
personal goals for lifestyle change, following the specific,
measurable, achievable, realistic and time-
bound principle. Participants receive automated reminders to enter
measurements (eg, number of steps and blood pressure)
for these goals, facilitating progress monitoring. The
intervention participants will receive support from an
experienced lifestyle coach, who is trained in motivational
interviewing and works according to a coach protocol
based on current guidelines for risk factor management.
Regular training sessions in each country will enhance
uniformity in coaching procedures, taking cultural differences into account. During the baseline visit, after randomisation, the coach discusses the participant’s dementia
risk profile, and a first lifestyle goal will be set through the
app. After the baseline visit, all communication between
the participant and coach will take place through the
messaging functionality. Through the coach portal, the
coach can view goals and measurements, send tailored
education modules, and offer remote support to facilitate
sustainable behaviour change.
Participants randomised to the control condition will
have access to the control app, which is similar in appearance but only contains education material, lacking interactive features and coach-support. During the baseline
visit, control participants will receive concise feedback on
their risk profile.
The PRODEMOS intervention in its current design is
positioned as add-on to existing care.
Primary and secondary outcomes
Following a type II hybrid design, primary outcomes for
effectiveness and implementation are equally important.
The primary effectiveness outcome is the change in the
Cardiovascular Risk Factors, Ageing and Incidence of
Dementia (CAIDE) dementia risk score between baseline
and 18-month follow-up.31 The main secondary effectiveness outcomes include change in the individual modifiable
components of the primary outcome, change in ten-year
cardiovascular disease (CVD) risk, cost-
effectiveness and
certain clinical outcomes such as incidence of mild cognitive
3
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Open access

impairment (MCI) and dementia. The operationalisation
of all effectiveness outcomes is listed in table 1.
Implementation outcomes include acceptability, adoption, appropriateness, feasibility, fidelity, coverage, sustainability and costs of the implementation. User statistics,
including data on goals set, messages sent and education
items read, will be analysed to assess adoption and sustained
use of the platform. In-depth interviews with participants
and coaches will focus on user experiences, particularly with
respect to barriers and facilitators for (sustained) platform
use. All implementation outcomes and evaluation methods
are shown in table 2.
Study logistics and data collection
The trial design is visualised in figure 2. All participants
will receive one phone call and make three visits to a study
venue during the study. Data are collected in electronic
case report forms that are accessible through the assessor
portal (figure 1).
Eligibility criteria that can be assessed remotely will be
checked by a local research team member through the
screening phone call. During the subsequent screening
visit, informed consent (online supplemental file 1) will
be obtained, and final eligibility will be assessed by administering the Mini-
Mental State Examination; measuring
blood pressure, Body Mass Index, waist circumference and
total cholesterol (capillary blood sample in the UK; venous
blood sample in China); and assessing physical activity,
smoking behaviour and a brief medical history. Weight will
4

be measured with a calibrated scale; blood pressure will be
measured twice with a calibrated, automated blood pressure
device. Screening visits will be performed by (GP) nurses
and local research team members specifically trained to
perform these measurements and will take place at the GP
surgery or a nearby community venue. Standard operating
procedures will be used to achieve uniform measurements
within and between countries.
After the screening visit, all participants will fill in eight
assessment questionnaires in the PRODEMOS app.
self-
These questionnaires will be used to assess secondary
outcomes (ie, physical activity, quality of life, well-being,
disability, depressive symptoms, self-management, anxiety
and diet; table 1) and potential barriers for lifestyle
behaviour change, which can inform coaches to tailor
their coaching strategy. Seven of these questionnaires
(ie, International Physical Activity Questionnaire—Short
Form, EuroQol Five Dimensions, ICEpop CAPability
Measure for Adults, WHO Disability Assessment Schedule
2.0, Geriatric Depression Scale (GDS), Partners In Health
and Hospital Anxiety and Depression Scale–Anxiety) have
been externally validated in both Western and Chinese
populations.32–45 Owing to obvious cultural differences, we
decided to use two different diet questionnaires that were
validated in the UK and Chinese population, respectively
(Short-Form Food Frequency Questionnaire and Kadoorie
Biobank Food Frequency Questionnaire).46 47
Eggink E, et al. BMJ Open 2021;11:e049762. doi:10.1136/bmjopen-2021-049762
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Figure 1 Overview of the prevention of dementia using mobile phone applications (PRODEMOS) platform and its
functionalities. Main features of coach portal: viewing and adjusting details of goals and measurements; sending and receiving
chat messages to and from the participants; sending education and news items. Main features of intervention app: setting and
adjusting goals; entering measurements; sending and receiving chat messages to and from the coach; reading education and
news items automatically pushed by platform or received from the coach; receiving periodic adverse event questionnaires and
self-assessment questionnaires. Main features of assessor portal: blinded collection of participant data through electronic case
report forms and questionnaires. The control application has similar connections with the assessor portal and the researcher
portal/database, but is not connected to the coach portal.

Open access

Primary outcome

Points

CAIDE Score (range: 0–15), which is composed of and calculated from the
following:
Age

 

 <47 years

0

 47–53

3

 >53

4

Education

 

 ≥10 years

0

 7–9 years

2

 <7 years

3

Gender

 

 Female

0

 Male

1

Systolic blood pressure

 

 ≤140 mm Hg

0

 >140 mm Hg

2

BMI

 
2

 ≤30 kg/m

0

 >30 kg/m2

2

Total cholesterol

 

 ≤6.5 mmol/L

0

 >6.5 mmol/L

2

Physical activity*

 

 Yes

0

 No

1

Secondary outcomes

 

Individual modifiable components of the
CAIDE score†

Estimated 10-year cardiovascular
risk

Number of uncontrolled risk factors

LIBRA dementia risk score

Active smoking

Number of hospital admissions

Medication adherence

Diet‡

Number of drugs

Disability§

Incident dementia¶

Anxiety**

Incident MCI¶

Self-management††

Incident cardiovascular disease¶,§§

Depressive symptoms‡‡

Incident diabetes¶

Quality of life¶¶

All-cause mortality

Cost-effectiveness

*Assessed according to WHO standard for physical activity of at least 150 min per
week.
†Physical activity assessed with the International Physical Activity Questionnaire—
Short Form.
‡Assessed with Short-Form Food Frequency Questionnaire (UK) and China Kadoorie
Biobank Food Frequency Questionnaire (China).
§Assessed with the WHO Disability Assessment Schedule.
¶Self-reported and cross-checked with general practitioner file.
**Assessed with the Hospital Anxiety and Depression Scale—Anxiety.
††Assessed with the Partners In Health.
‡‡Assessed with the Geriatric Depression Scale.
§§Defined as myocardial infarction or stroke.
¶¶Assessed with the ICEpop CAPability Measure for Adults and EuroQol Five
Dimensions Three Levels.
BMI, Body Mass Index; CAIDE, Cardiovascular Risk Factors, Ageing and Incidence of
Dementia; LIBRA, Lifestyle for Brain Health; MCI, mild cognitive impairment.

The baseline visit will be conducted face-
to-
face by
the health coach at the GP practice or local community
venue. During this visit, self-assessment questionnaires are
Eggink E, et al. BMJ Open 2021;11:e049762. doi:10.1136/bmjopen-2021-049762

reviewed, relevant medical history and medication use are
recorded, and participants are randomly assigned to one
of the treatment conditions. Only intervention participants will set a first lifestyle goal together with the coach,
according to their dementia risk profile.
All participants will receive periodic adverse event (AE)
questionnaires in the app, assessing incident dementia,
MCI, CVD and diabetes. All self-reported outcomes will be
verified with the participant’s treating physician.
After 18 months, the questionnaires and all measurements performed during the screening and baseline visit
are repeated during the final visit.
Randomisation and blinding
After completion of the baseline assessments, participants
will be individually randomised in a 1:1 ratio, stratified by
country, using a central, computer-generated sequence.
Participating cohabiting partners will be allocated to the
same study condition. Complete blinding of participants
is not possible, owing to the nature of the intervention.
Participants will be informed that they will be randomised
to one of two lifestyle apps, without further details. All
outcome assessments will be done by an independent
assessor unaware of treatment allocation.
Safety and privacy
Due to the nature of the intervention, serious AEs are
unlikely to occur, and we consider the intervention low
risk. A data safety and monitoring board is not installed.
Some precautions are taken to optimise participant
safety. First, regardless of their study allocation, participants will be referred to their GP or treating physician
if deemed necessary based on their baseline or outcome
parameters and local guidelines. Second, AEs will be
monitored through three 6 monthly questionnaires,
for which participants will receive notifications on their
smartphone and reminders through email (UK) or SMS
(China). If the participant is not able to fill in the questionnaire, an informant can be contacted. A blinded
researcher will, with explicit permission gained through
the informed consent procedure, cross-check all reported
AEs by consulting the participant’s GP or treating
physician. Third, the PRODEMOS platform is built in
accordance with the highest security requirements in
healthcare. It complies with NEN 7510, the Health Insurance Portability and Accountability Act, ISO 133485 and
General Data Protection Regulation.
Protocol adjustments due to COVID-19 pandemic
As a result of the COVID-19 pandemic and related local
research restrictions, certain adjustments have been made
to the original study protocol as published on the International Standard Randomised Controlled Trial Number
Register (ISRCTN). First, recruitment was planned to
start in early 2020 but had to be suspended until January
2021. Second, as it is difficult to predict the development
of the pandemic and associated restrictions, we have
slightly amended the study protocol to allow for flexible
5
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Method

Outcome

Measurement

Population*

Timing of
assessment

Quantitative

Coverage

(Non)Response rates, comparison
characteristics of participants with eligible
population

Potential target population

At baseline

Adoption

Utilisation, usage, and uptake

Intervention participants,
coaches

After 2 weeks

Appropriateness

Short questionnaire of perceived fit or
relevance in the target population and the
coaches

Intervention participants,
coaches

After 3 months and at
study end

Acceptability

Short questionnaire of agreeability, user-
friendliness, credibility

Intervention participants,
coaches

After 3 months and at
study end

Sustainability

Adherence, dropout

Intervention participants,
dropouts†

Throughout the study

Cost

Implementation costs

N.A.

N.A.

Feasibility

The extent to which the mHealth intervention
can be carried out →practical and social
barriers/facilitators

Intervention participants,
dropouts,† coaches

After 3 months and at
study end

Appropriateness

Perceived fit or relevance in the target
population

Intervention participants,
dropouts,† coaches

After 3 months and at
study end

Acceptability

Agreeability, user-friendliness, credibility

Intervention participants,
dropouts,† coaches

After 3 months and at
study end

Fidelity

Degree to which the mHealth application
is implemented compared with the original
protocol

N.A.

After the study

Qualitative

*For all analyses, a Chinese and UK population will be involved.
†Study dropouts will be asked to participate in a short exit interview.
mHealth, mobile health.

measurement procedures at baseline that can be operationalised in either one or two face-to-face visits and for a
flexible intervention duration of 12–18 months. However,
we will strive for a follow-up period of 18 months in as
many participants as possible.
Patient and public involvement
We have received valuable input into the design of the
study and mHealth platform from multiple interactive
sessions with GPs, health coaches, researchers, representatives of people living with dementia, community
leaders and policy makers. Needs and views regarding the
intervention were assessed through interviews and focus
groups with potential end users in both countries. All
patient-facing material used in the UK has been reviewed
by potential end users. Qualitative evaluations of the
pilot study with research staff, coaches and patient participants were used to refine the intervention and study
procedures.
Statistical analysis
Sample size
The CAIDE Score will be used as primary effectiveness outcome. We decided to use a difference of 0.186
points on the CAIDE Score between the average of
both study groups as a minimum target threshold,
because this difference was observed in the Prevention
of Dementia by Intensive Vascular Care trial after 2
6

years (p=0.005; intervention group=−0.290±1.47 SD and
control group=−0.104±1.36 SD). Attrition after 2 years of
follow-up was 21% in this study.14 With 80% power, a 0.05
two-sided significance level, accounting for 21% attrition,
and a mean difference in change in CAIDE of 0.186, the
required sample size is estimated to be 2319 participants.
To allow for unexpected factors, we raised this to 2400.
Data analysis
The effect on the CAIDE Score will be analysed using
linear mixed-effect models according to the intention-
to-treat principle, taking clustering within partner pairs
and country into account by testing best fit for random
intercept and/or slope. If needed, we will adjust for baseline imbalances and take clustering of the intervention
within centre and/or coach into account. No imputation
of the CAIDE Score will be done for the primary analysis.
In sensitivity analyses, we will use multiple imputation
to assess the impact of missing items needed to calculate the CAIDE Score, provided there are no indications
that the variables are missing not at random, and a per-
protocol analysis for those adherent to the intervention
will be performed. Moreover, we will explore the interaction of intervention duration with the effect of the
invention by adding an interaction term (intervention
duration*randomisation group) to the main model. This
will give insight into the potential additional intervention
Eggink E, et al. BMJ Open 2021;11:e049762. doi:10.1136/bmjopen-2021-049762
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Table 2 Summary of implementation research methods and outcomes
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effect in participants with a follow-up time of less than 18
months.
Subgroup analyses will be performed for country, sex,
age group, having a history of CVD, number of risk factors,
willingness to change lifestyle (assessed with one question during the baseline visit), participation with(out) a
participating partner, having the same coach during the
full length of the study and the number of goals set. For
all these factors, interaction terms will be included to test
for between-subgroup differences in intervention effects.
The effect on individual modifiable components of the
CAIDE Score and 10-year CVD Risk Scores will be analysed
using linear mixed-effect models according to the intention-
to-
treat principle, taking clustering within partner pairs
and country into account. Self-assessment scales, which are
Eggink E, et al. BMJ Open 2021;11:e049762. doi:10.1136/bmjopen-2021-049762

mostly ordinal, will be regarded as linear scales if there are
at least four categories and the ‘distance’ between the categories can be regarded equal. Poisson regression or zero-
inflated models may be applied to distributions resembling
count or zero-inflated data. The choice of the final model
will be a compromise between optimal fit and interpretability of the results for a general clinical public.
Prevalence ratios will be used for self-assessment instruments with defined cut-offs for the presence or absence
of a condition, for example, ‘depressive symptoms’ for a
GDS >5. For (clinical) dichotomous outcomes, such as
incident CVD, dementia or mortality, Cox proportional
hazard models will be used with time using baseline as
timescale. A sensitivity analysis will be performed using
age as timescale.
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Figure 2 Trial design. AE, adverse event; ISCED, International Standard Classification of Education; MMSE, Mini-Mental State
Examination; RCT, randomised controlled trial.

Open access

Pilot study
Between December 2019 and March 2020, a 6-week pilot
study was conducted in the Brighton and Sussex area,
the UK. Since the main aim was to test study logistics and
functionality of the intervention app, participants were
randomised in a 3:1 (intervention/control) ratio. An invitation letter was sent to 600 potentially eligible patients
from two GPs. The response rate was 14.8% (n=89), of
whom 21 participants (3.5%) could be included. The
main reasons for exclusion were not living in the designated postal code area and having <2 dementia risk
factors. Participants had a median age of 69 years old, and
12 (57%) were men. Fifteen participants were allocated
to the intervention group and six to the control group.
During the pilot study, 10 of 15 intervention participants set at least one goal (range: 1–8 goals). Goals were
set in five domains, including physical activity, healthy
diet, body weight, blood pressure and cholesterol. Six
of ten participants entered goal-related measurements
(range: 2–243 measurements). All intervention participants used the chat functionality to consult the coach. In
total, 278 messages were sent back and forth, that is, on
average three messages per intervention participant per
week.
The pilot study was evaluated through qualitative
sessions with the participants and coaches. The main
adjustments based on the participants’ feedback included
improvements to the chat functionality (allowing attachments and larger font size), simplification of the functionality to enter and view measurements, setting the
first goal together with the coach and more detailed
instructions for app use through an instruction video and
written manual. Based on feedback from the coaches, we
improved the functionalities for population management
in the coach portal, including an input screen to make
notes about individual participants and a functionality to
send education material to (groups of) participants.
A similar pilot study will be conducted in China, to
test platform functionality and study logistics in all seven
participating trial centres.

DISCUSSION
In the PRODEMOS study, we will investigate the implementation of a self-management mHealth intervention
with remote coaching and its effect on dementia risk over
18 months. We will target people aged 55–75 years old
with elevated dementia risk of low SES in the UK and of
any SES in the Beijing and Tai’an cities in China, as these
populations are usually not reached by preventive strategies and may benefit the most. User data and qualitative
8

analysis of our pilot study suggest that our mHealth application, after further adaptations to improve attractiveness
and usability, is now ready to be studied in older adults
who are interested in participating in a study on lifestyle
change to lower their overall dementia risk.
The HATICE trial has shown that a coach-supported
internet platform can improve cardiovascular risk factors
in European elderly. Although we build on these experiences, the modality (ie, app instead of internet platform) and target population are different. The resulting
uncertainty that there would be a similar benefit of our
intervention renders the use of a hybrid effectiveness–
implementation design highly suitable.27
Strengths
Chronic disease risk is largely affected by socioeconomic
factors, including psychological, cultural and economic
characteristics, requiring preventive strategies that take
these aspects into account.48 In PRODEMOS, we aim to
support individuals by offering intensive human support
through the app and by aligning the intervention with
the healthcare system. In order to eventually embed a
complex prevention intervention into primary healthcare, it is crucial to involve and consult all stakeholders,
such as GPs, practice nurses, and end users.49 In the
current hybrid effectiveness–implementation study, we
take some first steps to explore the possibilities and challenges for embedding the intervention in existing healthcare. This study will provide concrete evidence of the
scale of the change that might be achieved for individuals
at risk, whether and how this approach is taken up within
diverse populations.
The PRODEMOS study is designed as one trial,
recruiting participants in two different countries,
increasing the external validity of the results. Overall,
both countries will follow the same research protocol and
highly similar standard operating procedures and will
investigate similar interventions. Through semistructured
interviews among the elderly in Beijing and the UK, we
learnt that needs and wishes regarding lifestyle behaviour
change through mHealth are largely similar (manuscripts currently being drafted). Therefore, the Chinese
and UK intervention will share the same functionalities
and coaching procedures. Given obvious cultural-related
and healthcare-related differences, certain aspects of the
study logistics, lifestyle support and layout of the app had
to be culturally adjusted. In a preplanned subgroup analysis, we will assess both effectiveness and implementation
outcomes for both countries separately.
Limitations
The study may yield some limitations. First, the optimal
age range for trials on dementia risk reduction is
unknown.15 There is a trade-off between potentially more
effective treatments in midlife and the chance to detect
treatment effects on cognitive outcomes in late life.4 As
in the current study, we are assessing both a dementia
Eggink E, et al. BMJ Open 2021;11:e049762. doi:10.1136/bmjopen-2021-049762
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The full analysis plan, including the health economic
analysis plan entailing the cost–consequence analysis of
the within-trial results, the cost-effectiveness analyses and
the cost–utility analysis and hypotheses for the subgroup
analyses, is published on the ISRCTN website: http://
www.isrctn.com/ISRCTN15986016.

Open access

ETHICS AND DISSEMINATION
The PRODEMOS trial is sponsored in the UK by the
University of Cambridge and is granted ethical approval
by the London–Brighton and Sussex Research Ethics
Committee (reference: 20/LO/01440). In China, the
trial is approved by the medical ethics committees of
Capital Medical University, Beijing Tiantan Hospital,
Beijing Geriatric Hospital, Chinese People’s Liberation
Army General Hospital, Taishan Medical University and
Xuanwu Hospital. Data will be exported in a pseudonymised format according to prevailing guidelines on good
clinical practice in both countries. Only anonymised data
will be exchanged between the UK, China and the Netherlands. The exported data will be stored centrally on a
protected server in the Netherlands, which is compatible with the highest standards of data management in
medical research. Results will be published in a peer-
reviewed journal.
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risk score and clinical outcomes; we have taken a pragmatic approach, targeting individuals aged 55–75 years
old15.
Second, change in CAIDE dementia risk score is not
easily translated into incidence of dementia. However,
although not specifically designed as RCT outcome
measure, the CAIDE Score can detect change over time.50
A third potential limitation is that, owing to the nature
of the intervention, blinding of the participants is only
partly possible. A certain degree of contamination might
occur, especially in communities that live closely together.
The study logistics and intervention are designed in
such a way as to limit contact between participants after
randomisation.
Finally, the results of the baseline measurements will be
revealed to all participants, potentially leading to treatment effects in both study conditions. Also, behaviour of
participants and their treating physicians may change in
both study conditions as a reaction to the awareness of
being part of the study (Hawthorne effect). Both mechanisms will perhaps mask (part of) the ‘true’ contrast
in dementia risk between the intervention and control
condition.
For the planned health economic analyses, we will
rely on economic modelling, based on the intermediate outcomes reflecting risk of dementia and CVD and
assumptions on their causality with the clinical endpoints
dementia and CVD, because the study is not designed nor
powered to detect an effect on these clinical endpoints.
The high prevalence of dementia, lower provision of
high-
quality cardiovascular preventive care in LMIC
and lower uptake of such programmes in Western low-
SES populations require affordable and straightforward
preventive strategies. If proven effective and implementable, our pragmatic smartphone intervention facilitates widespread use and reduction of dementia risk for
hard-to-reach populations across the globe.
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